Pratt M C, Lewis-Barned N J, Walker R J, Bailey R R, Shand B I, Livesey J
Department of Medicine, Otago Medical School, Dunedin, New Zealand.
Br J Clin Pharmacol. 1992 Oct;34(4):363-5. doi: 10.1111/j.1365-2125.1992.tb05644.x.
The possibility that the ACE inhibitors, enalapril and captopril, may decrease plasma EPO concentrations was studied in a single-blind, cross-over study in 10 healthy volunteers. Plasma EPO concentrations, haemoglobin concentration, red blood cell count, plasma creatinine concentration and mean arterial pressure were measured at baseline and after 28 days treatment with both ACE inhibitors. A significant fall in mean plasma EPO concentration occurred with both ACE inhibitors and returned to baseline after stopping the drugs. It is likely that ACE inhibitors decrease EPO formation, by inhibition of angiotensin-II production. This effect could be important in patients with renal failure, renal transplantation or other chronic conditions with an associated anaemia. Haematological parameters should be monitored in such patients when they are treated with an ACE inhibitor.
在一项针对10名健康志愿者的单盲交叉研究中，对血管紧张素转换酶（ACE）抑制剂依那普利和卡托普利可能降低血浆促红细胞生成素（EPO）浓度的可能性进行了研究。在基线时以及使用这两种ACE抑制剂治疗28天后，测量血浆EPO浓度、血红蛋白浓度、红细胞计数、血浆肌酐浓度和平均动脉压。两种ACE抑制剂均导致平均血浆EPO浓度显著下降，停药后恢复至基线水平。ACE抑制剂可能通过抑制血管紧张素II的产生来减少EPO的形成。这种效应在肾衰竭、肾移植或其他伴有贫血的慢性疾病患者中可能很重要。当此类患者接受ACE抑制剂治疗时，应监测血液学参数。
